CVS Health Corporation logo

CVS Health Corporation (CVS)

Market Closed
3 Mar, 20:00
NYSE NYSE
$
80. 49
-1.17
-1.43%
Pre Market
$
80. 48
-0.01 -0.01%
96.93B Market Cap
11.4 P/E Ratio
0.97% Div Yield
7,086,834 Volume
7.87 Eps
$ 81.66
Previous Close
Day Range
79.2 81.69
Year Range
58.35 85.15
Want to track CVS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
CVS earnings report is expected in 56 days (29 Apr 2026)
CVS Health Stock Among the Worst to Own in February

CVS Health Stock Among the Worst to Own in February

Volatility is plaguing Wall Street in light of President Donald Trump's tariffs.

Schaeffersresearch | 1 year ago
CVS Health's Pre-Q4 Earnings: Time to Buy, Hold or Sell the Stock?

CVS Health's Pre-Q4 Earnings: Time to Buy, Hold or Sell the Stock?

Given that CVS Health's restructuring plan is described as enterprise-wide and ongoing, it is reasonable to expect significant charges in the fourth quarter.

Zacks | 1 year ago
CVS Health (CVS) Stock Declines While Market Improves: Some Information for Investors

CVS Health (CVS) Stock Declines While Market Improves: Some Information for Investors

CVS Health (CVS) closed the most recent trading day at $56.82, moving -0.14% from the previous trading session.

Zacks | 1 year ago
CVS Health stock price is recovering: Feb 12 will be crucial

CVS Health stock price is recovering: Feb 12 will be crucial

CVS Health stock has moved from one of the worst performers in the S&P 500 index in 2024 to the second-best performer this year. It has risen in the last six consecutive weeks and is hovering at its highest level since December 2.

Invezz | 1 year ago
CVS and Other Healthcare Stocks Are Soaring. Why the Sector Is No Longer Sick.

CVS and Other Healthcare Stocks Are Soaring. Why the Sector Is No Longer Sick.

Healthcare stocks are cheap. Earnings are expected to grow solidly, and RFK Jr. won't change that.

Barrons | 1 year ago
Should You Buy CVS Health Stock Before Feb. 12?

Should You Buy CVS Health Stock Before Feb. 12?

CVS Health (CVS 2.01%) is a big name in healthcare, and it has generally been seen as a good way to invest in the industry. In addition to its pharmacy retail operations, the company has a pharmacy benefits management business.

Fool | 1 year ago
Is Most-Watched Stock CVS Health Corporation (CVS) Worth Betting on Now?

Is Most-Watched Stock CVS Health Corporation (CVS) Worth Betting on Now?

Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.

Zacks | 1 year ago
Momentum Grows for These 3 Healthcare Stocks

Momentum Grows for These 3 Healthcare Stocks

Today's stock market has brought about a set of distracting indicators and methods to analyze a potential trade—or investment—opportunity, some of which might be accurate in a completely binary setting. What most investors fail to realize is that all of these indicators and methods rely on price action, which is why today's list cuts down all the noise to focus on one indicator alone.

Marketbeat | 1 year ago
CVS Health (CVS) Increases Despite Market Slip: Here's What You Need to Know

CVS Health (CVS) Increases Despite Market Slip: Here's What You Need to Know

In the latest trading session, CVS Health (CVS) closed at $54.55, marking a +1.36% move from the previous day.

Zacks | 1 year ago
Walgreens Boots Alliance vs. CVS Health: What's the Better Turnaround Play?

Walgreens Boots Alliance vs. CVS Health: What's the Better Turnaround Play?

Investing in pharmacy chains hasn't been a good move in recent years. Rite Aid filed for (and emerged from) bankruptcy, and while its larger rivals aren't in as dire shape, they aren't exactly flourishing.

Fool | 1 year ago
Wall Street Analysts See CVS Health (CVS) as a Buy: Should You Invest?

Wall Street Analysts See CVS Health (CVS) as a Buy: Should You Invest?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Zacks | 1 year ago
CVS Health Isn't Going To The Dogs

CVS Health Isn't Going To The Dogs

CVS Health's poor 2024 performance was driven by negative macro and micro factors.  Investors became too pessimistic about the company's forward prospects. A new CEO is a catalyst. Despite weak 2024 financial results, CVS is likely to begin to rebound in 2025.  The company remains free cash flow positive, despite myriad challenges.

Seekingalpha | 1 year ago
Loading...
Load More